Literature DB >> 22493364

Methylation of the DFNA5 gene is frequently detected in colorectal cancer.

Kazuaki Yokomizo1, Yoshikuni Harada, Kazuhiro Kijima, Kazuki Shinmura, Makiko Sakata, Kazuma Sakuraba, Youhei Kitamura, Atsushi Shirahata, Tetsuhiro Goto, Hiroki Mizukami, Mitsuo Saito, Gaku Kigawa, Hiroshi Nemoto, Kenji Hibi.   

Abstract

BACKGROUND: Recently, the human deafness, autosomal dominant 5 gene, DFNA5, has frequently been detected in cancer tissues. The methylation status of the DFNA5 gene in colorectal cancer was examined and was compared to the clinocopathological findings.
MATERIALS AND METHODS: Eighty-five tumor samples and corresponding normal tissues were obtained from patients with colorectal cancer who underwent surgery at our hospital. The methylation status of the DFNA5 gene in these samples was examined by quantitative methylation-specific PCR (qMSP). Subsequently, the clinicopathological findings were correlated with the methylation status of the DFNA5 gene.
RESULTS: DFNA5 gene methylation was found in 29 (34%) out of the 85 colorectal carcinomas, suggesting that it was frequently observed in colorectal cancer. A significant correlation with methylation was observed for lymphatic vessel invasion and TNM stage (p=0.0268 and p=0.0189, respectively).
CONCLUSION: DFNA5 might act as a tumor suppressor gene and DFNA5 gene methylation might play an important role in the development of colorectal cancer. Our data implicate DFNA5 gene methylation as a novel molecular biomarker in colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22493364

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  26 in total

1.  Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin.

Authors:  Yupeng Wang; Wenqing Gao; Xuyan Shi; Jingjin Ding; Wang Liu; Huabin He; Kun Wang; Feng Shao
Journal:  Nature       Date:  2017-05-01       Impact factor: 49.962

2.  DFNA5 inhibits colorectal cancer proliferation by suppressing the mTORC1/2 signaling pathways via upregulation of DEPTOR.

Authors:  Jing Guo; Junhui Yu; Mingchao Mu; Zilu Chen; Zhengshui Xu; Chenye Zhao; Kui Yang; Jianbao Zheng; Xiao Qin; Wei Zhao; Xuejun Sun
Journal:  Cell Cycle       Date:  2022-08-03       Impact factor: 5.173

3.  Study of methylation of histone H3 lysine 9 and H3 lysine 27 during X chromosome inactivation in three types of cells.

Authors:  Yan Li; Tan Tan; Le Zong; Dacheng He; Wei Tao; Qianjin Liang
Journal:  Chromosome Res       Date:  2012-09-06       Impact factor: 5.239

Review 4.  Inflammatory cell death in intestinal pathologies.

Authors:  Deepika Sharma; Thirumala-Devi Kanneganti
Journal:  Immunol Rev       Date:  2017-11       Impact factor: 12.988

5.  Antitumor Effect of Simvastatin in Combination With DNA Methyltransferase Inhibitor on Gastric Cancer via GSDME-Mediated Pyroptosis.

Authors:  Ying Xia; Yong Jin; Daxiang Cui; Xia Wu; Cunfeng Song; Weilin Jin; Hai Huang
Journal:  Front Pharmacol       Date:  2022-04-20       Impact factor: 5.988

6.  Sudden bilateral hearing loss in gastric cancer as the only symptom of disease.

Authors:  Zoran Rakusic; Ana Misir Krpan; Darija Stupin Polancec; Antonia Jakovcevic; Vesna Bisof
Journal:  Onco Targets Ther       Date:  2015-06-02       Impact factor: 4.147

Review 7.  Double agents of cell death: novel emerging functions of apoptotic regulators.

Authors:  Heather M Lamb
Journal:  FEBS J       Date:  2020-04-11       Impact factor: 5.542

8.  Differential Expression and Copy Number Variation of Gasdermin (GSDM) Family Members, Pore-Forming Proteins in Pyroptosis, in Normal and Malignant Serous Ovarian Tissue.

Authors:  Caglar Berkel; Ercan Cacan
Journal:  Inflammation       Date:  2021-06-06       Impact factor: 4.092

9.  Role of DFNA5 in hearing loss and cancer - a comment on Rakusic et al.

Authors:  Lieselot Croes; Ken Op de Beeck; Guy Van Camp
Journal:  Onco Targets Ther       Date:  2015-09-15       Impact factor: 4.147

10.  Recursive Random Lasso (RRLasso) for Identifying Anti-Cancer Drug Targets.

Authors:  Heewon Park; Seiya Imoto; Satoru Miyano
Journal:  PLoS One       Date:  2015-11-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.